New angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration

Journal of Medicinal Chemistry

Volumn 53, Issue 7, 2010, Pages 2814-2824

  Ché, Christian ^a   Yang, Gaoqiang ^a   Thiot, Carine ^a   Lacoste, Marie Claude ^a   Currie, Jean Christophe ^b   Demeule, Michel ^a   Régina, Anthony ^a   Béliveau, Richard ^b   Castaigne, Jean Paul ^a  

^a ANGIOCHEM INC   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANG 1007; ANG 1009; DIMETHYLGLYCINE ETOPOSIDE; DOXORUBICIN; ETOPOSIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN TISSUE; CANCER CELL CULTURE; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG PENETRATION; DRUG SYNTHESIS; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; TRANSCYTOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MALE; MICE; P-GLYCOPROTEINS; PEPTIDES;

EID: 77950563375     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9016637     Document Type: Article

References (46)

1. Kleisbauer, J. P.; Vesco, D.; Orehek, J.; Blaive, B.; Clary, C.; Poirier, R.; Saretto, S.; Carles, P.; Dongay, G.; Guerin, J. C. Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Cooperative study from the Groupe Français Pneumo-Cancerologie Eur. J. Cancer Clin. Oncol. 1988, 24 (2) 131 - 135
2. Kobayashi, T.; Yoshida, J.; Ishiyama, J.; Noda, S.; Kito, A.; Kida, Y. Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumors. An experimental and clinical study J. Neurosurg. 1989, 70 (5) 676 - 681
3. Weiss, R. B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 1992, 19 (6) 670 - 686
4. Henderson, I. C.; Canellos, G. P. Cancer of the breast: the past decade (second of two parts) N. Engl. J. Med. 1980, 302 (2) 78 - 90
5. Fornari, F. A.; Randolph, J. K.; Yalowich, J. C.; Ritke, M. K.; Gewirtz, D. A. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells Mol. Pharmacol. 1994, 45 (4) 649 - 656
6. Lee, J. S.; Murphy, W. K.; Glisson, B. S.; Dhingra, H. M.; Holoye, P. Y.; Hong, W. K. Primary chemotherapy of brain metastasis in small-cell lung cancer J. Clin. Oncol. 1989, 7 (7) 916 - 922
7. Baldwin, E. L.; Osheroff, N. Etoposide, topoisomerase II and cancer Curr. Med. Chem. Anticancer Agents 2005, 5 (4) 363 - 372
8. Bart, J.; Groen, H. J.; Hendrikse, N. H.; van der Graaf, W. T.; Vaalburg, W.; de Vries, E. G. The blood-brain barrier and oncology: new insights into function and modulation Cancer Treat. Rev. 2000, 26 (6) 449 - 462
9. Cecchelli, R.; Berezowski, V.; Lundquist, S.; Culot, M.; Renftel, M.; Dehouck, M. P.; Fenart, L. Modelling of the blood-brain barrier in drug discovery and development Nat. Rev. Drug. Discovery 2007, 6 (8) 650 - 661
10. Pardridge, W. M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 2003, 3 (2), 90 - 105, 151.
11. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development NeuroRx 2005, 2 (1) 3 - 14
12. Pardridge, W. M. Drug targeting to the brain Pharm. Res. 2007, 24 (9) 1733 - 1744
13. Demeule, M.; Currie, J. C.; Bertrand, Y.; Che, C.; Nguyen, T.; Regina, A.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2 J. Neurochem. 2008, 106 (4) 1534 - 1544
14. Loscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family NeuroRx 2005, 2 (1) 86 - 98
15. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain J. Pharmacol. Exp. Ther. 2008, 324 (3) 1064 - 1072
16. Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J. P. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2 Br. J. Pharmacol. 2008, 155 (2) 185 - 197
17. Drappatz, J.; Brenner, A.; Rosenfeld, S.; Schiff, D.; Wen, P.; Mikkelsen, T.; Groves, M.; Wong, E. T.; Eichler, A.; Elian, K. M.; Lawrence, B.; Demeule, M.; Castaigne, J. P. ANG1005: Development of a new Engineered Peptide Compound (EPiC) for the Treatment of Malignant Glioma. Poster presented at: Neuroscience 2009, Chicago, IL, October 18, 2009.
18. Kurzrock, R.; Gabrail, N.; Moulder, S.; Brenner, A.; Guo, Z.; Bouchard, D.; Churchill, W.; Bento, P.; Fitsialos, D.; Fraitag, B.; Neale, A.; Castaigne, J. P.; Sarantopoulos, J. ANG1005: A promising new Engineered Peptide Compound (EPiC) for Patients with Advanced Solid Tumors and Brain Metastases. Poster presented at: Neuroscience 2009, Chicago, IL, October 18, 2009.
19. Zhang, K.; Franz, A.; Hill, G. C.; McCallum, C. M.; Minch, M. J. Etoposide: conformational and hydration features Magn. Reson. Chem. 1999, 37 (11) 788 - 798
20. Ling, Y. H.; el-Naggar, A. K.; Priebe, W.; Perez-Soler, R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells Mol. Pharmacol. 1996, 49 (5) 832 - 841
21. Krishan, A.; Paika, K.; Frei, E., III. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts J. Cell Biol. 1975, 66 (3) 521 - 530
22. ETOPOPHOS - Etoposide Phosphate Injection, Powder, Lyophilized, for Solution [package insert]; Bristol-Myers Squibb Company: Princeton, NJ, 2005.
23. Doxorubicin Hydrochloride for Injection [package insert]; Pfizer Inc.: New York, 2006.
24. Dagenais, C.; Rousselle, C.; Pollack, G. M.; Scherrmann, J. M. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice J. Cereb. Blood Flow Metab. 2000, 20 (2) 381 - 386
25. Cisternino, S.; Rousselle, C.; Dagenais, C.; Scherrmann, J. M. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice Pharm. Res. 2001, 18 (2) 183 - 190
26. Duvernoy, H.; Delon, S.; Vannson, J. L. The vascularization of the human cerebellar cortex Brain Res. Bull. 1983, 11 (4) 419 - 480
27. Lage, H. An overview of cancer multidrug resistance: a still unsolved problem Cell. Mol. Life Sci. 2008, 65 (20) 3145 - 3167
28. Pauwels, E. K.; Erba, P.; Mariani, G.; Gomes, C. M. Multidrug resistance in cancer: its mechanism and its modulation Drug News Perspect. 2007, 20 (6) 371 - 377
29. Perez-Tomas, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment Curr. Med. Chem. 2006, 13 (16) 1859 - 1876
30. Borst, P.; Elferink, R. O. Mammalian ABC transporters in health and disease Annu. Rev. Biochem. 2002, 71, 537 - 592
31. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.; Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 1999, 39, 361 - 398
32. Devault, A.; Gros, P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities Mol. Cell. Biol. 1990, 10 (4) 1652 - 1663
33. Gros, P.; Croop, J.; Housman, D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins Cell 1986, 47 (3) 371 - 380
34. Gros, P.; Raymond, M.; Bell, J.; Housman, D. Cloning and characterization of a second member of the mouse mdr gene family Mol. Cell. Biol. 1988, 8 (7) 2770 - 2778
35. Raymond, M.; Gros, P. Mammalian multidrug-resistance gene: correlation of exon organization with structural domains and duplication of an ancestral gene Proc. Natl. Acad. Sci. U.S.A. 1989, 86 (17) 6488 - 6492
36. Schinkel, A. H. P-Glycoprotein, a gatekeeper in the blood-brain barrier Adv Drug Delivery Rev. 1999, 36 (2-3) 179 - 194
37. Schinkel, A. H.; Mayer, U.; Wagenaar, E.; Mol, C. A.; van Deemter, L.; Smit, J. J.; van der Valk, M. A.; Voordouw, A. C.; Spits, H.; van Tellingen, O.; Zijlmans, J. M.; Fibbe, W. E.; Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (8) 4028 - 4033
38. Schinkel, A. H.; Smit, J. J.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; van der Valk, M. A.; Robanus-Maandag, E. C.; te Riele, H. P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 1994, 77 (4) 491 - 502
39. Doyle, L. A.; Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 2003, 22 (47) 7340 - 7358
40. Yuan, J.; Lv, H.; Peng, B.; Wang, C.; Yu, Y.; He, Z. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer Cancer Chemother. Pharmacol. 2009, 63 (6) 1103 - 1110
41. Thomas, F. C.; Taskar, K.; Rudraraju, V.; Goda, S.; Thorsheim, H. R.; Gaasch, J. A.; Mittapalli, R. K.; Palmieri, D.; Steeg, P. S.; Lockman, P. R.; Smith, Q. R. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer Pharm. Res. 2009, 26 (11) 2486 - 2494
42. Simpson, I. A.; Appel, N. M.; Hokari, M.; Oki, J.; Holman, G. D.; Maher, F.; Koehler-Stec, E. M.; Vannucci, S. J.; Smith, Q. R. Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited J. Neurochem. 1999, 72 (1) 238 - 247
43. Seelbach, M. J.; Brooks, T. A.; Egleton, R. D.; Davis, T. P. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein J. Neurochem. 2007, 102 (5) 1677 - 1690
44. Pan, W.; Kastin, A. J.; Zankel, T. C.; van Kerkhof, P.; Terasaki, T.; Bu, G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier J. Cell Sci. 2004, 117 (Pt 21) 5071 - 5078
45. Gabathuler, R.; Demeule, M.; Regina, A.; Che, C.; Beliveau, R.; Castaigne, J. P. Development of a new Engineered Peptide Compound (EPiC) platform for the transport of small and large therapeutics to the CNS. Poster presented at: Neuroscience 2009, Chicago, IL, October 18, 2009.
46. Canadian Council on Animal Care. Good animal practice in science; http://www.ccac.ca/ (Accessed July, 2009).